Association of Wearable Device Use With Pulse Rate and Health Care Use in Adults With Atrial Fibrillation
- PMID: 34042996
- PMCID: PMC8160588
- DOI: 10.1001/jamanetworkopen.2021.5821
Association of Wearable Device Use With Pulse Rate and Health Care Use in Adults With Atrial Fibrillation
Abstract
Importance: Increasingly, individuals with atrial fibrillation (AF) use wearable devices (hereafter wearables) that measure pulse rate and detect arrhythmia. The associations of wearables with health outcomes and health care use are unknown.
Objective: To characterize patients with AF who use wearables and compare pulse rate and health care use between individuals who use wearables and those who do not.
Design, setting, and participants: This retrospective, propensity-matched cohort study included 90 days of follow-up of patients in a tertiary care, academic health system. Included patients were adults with at least 1 AF-specific International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) code from 2017 through 2019. Electronic medical records were reviewed to identify 125 individuals who used wearables and had adequate pulse-rate follow-up who were then matched using propensity scores 4 to 1 with 500 individuals who did not use wearables. Data were analyzed from June 2020 through February 2021.
Exposure: Using commercially available wearables with pulse rate or rhythm evaluation capabilities.
Main outcomes and measures: Mean pulse rates from measures taken in the clinic or hospital and a composite health care use score were recorded. The composite outcome included evaluation and management, ablation, cardioversion, telephone encounters, and number of rate or rhythm control medication orders.
Results: Among 16 320 patients with AF included in the analysis, 348 patients used wearables and 15 972 individuals did not use wearables. Prior to matching, patients using wearables were younger (mean [SD] age, 64.0 [13.0] years vs 70.0 [13.8] years; P < .001) and healthier (mean [SD] CHA2DS2-VASc [congestive heart failure, hypertension, age ≥ 65 years or 65-74 years, diabetes, prior stroke/transient ischemic attack, vascular disease, sex] score, 3.6 [2.0] vs 4.4 [2.0]; P < .001) compared with individuals not using wearables, with similar gender distribution (148 [42.5%] women vs 6722 women [42.1%]; P = .91). After matching, mean pulse rate was similar between 125 patients using wearables and 500 patients not using wearables (75.01 [95% CI, 72.74-77.27] vs 75.79 [95% CI, 74.68-76.90] beats per minute [bpm]; P = .54), whereas mean composite use score was higher among individuals using wearables (3.55 [95% CI, 3.31-3.80] vs 3.27 [95% CI, 3.14-3.40]; P = .04). Among measures in the composite outcome, there was a significant difference in use of ablation, occurring in 22 individuals who used wearables (17.6%) vs 37 individuals who did not use wearables (7.4%) (P = .001). In the regression analyses, mean composite use score was 0.28 points (95% CI, 0.01 to 0.56 points) higher among individuals using wearables compared with those not using wearables and mean pulse was similar, with a -0.79 bpm (95% CI -3.28 to 1.71 bpm) difference between the groups.
Conclusions and relevance: This study found that follow-up health care use among individuals with AF was increased among those who used wearables compared with those with similar pulse rates who did not use wearables. Given the increasing use of wearables by patients with AF, prospective, randomized, long-term evaluation of the associations of wearable technology with health outcomes and health care use is needed.
Conflict of interest statement
Figures
Similar articles
-
Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial.JAMA. 2018 Jul 10;320(2):146-155. doi: 10.1001/jama.2018.8102. JAMA. 2018. PMID: 29998336 Free PMC article. Clinical Trial.
-
Wearable Devices, Health Care Use, and Psychological Well-Being in Patients With Atrial Fibrillation.J Am Heart Assoc. 2024 Aug 6;13(15):e033750. doi: 10.1161/JAHA.123.033750. Epub 2024 Jul 16. J Am Heart Assoc. 2024. PMID: 39011944
-
Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial.JAMA Netw Open. 2021 Aug 2;4(8):e2121867. doi: 10.1001/jamanetworkopen.2021.21867. JAMA Netw Open. 2021. PMID: 34448866 Free PMC article. Clinical Trial.
-
Wearables in cardiology: Here to stay.Heart Rhythm. 2020 May;17(5 Pt B):889-895. doi: 10.1016/j.hrthm.2020.02.023. Heart Rhythm. 2020. PMID: 32354455 Review.
-
Keeping Pace with Wearables: A Living Umbrella Review of Systematic Reviews Evaluating the Accuracy of Consumer Wearable Technologies in Health Measurement.Sports Med. 2024 Nov;54(11):2907-2926. doi: 10.1007/s40279-024-02077-2. Epub 2024 Jul 30. Sports Med. 2024. PMID: 39080098 Free PMC article. Review.
Cited by
-
Artificial intelligence-enabled atrial fibrillation detection using smartwatches: current status and future perspectives.Front Cardiovasc Med. 2024 Jul 15;11:1432876. doi: 10.3389/fcvm.2024.1432876. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39077110 Free PMC article. Review.
-
Exploring Disparities in Healthcare Wearable Use among Cardiovascular Patients: Findings from a National Survey.Rev Cardiovasc Med. 2023 Nov 9;24(11):307. doi: 10.31083/j.rcm2411307. eCollection 2023 Nov. Rev Cardiovasc Med. 2023. PMID: 39076432 Free PMC article.
-
Consumer wearable devices for evaluation of heart rate control using digoxin versus beta-blockers: the RATE-AF randomized trial.Nat Med. 2024 Jul;30(7):2030-2036. doi: 10.1038/s41591-024-03094-4. Epub 2024 Jul 15. Nat Med. 2024. PMID: 39009776 Free PMC article. Clinical Trial.
-
Wearable health monitoring: wave of the future or waste of time?Glob Cardiol Sci Pract. 2024 Apr 20;2024(3):e202421. doi: 10.21542/gcsp.2024.21. eCollection 2024 Apr 20. Glob Cardiol Sci Pract. 2024. PMID: 38983747 Free PMC article. Review.
-
Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease.PLoS One. 2024 Jun 25;19(6):e0304644. doi: 10.1371/journal.pone.0304644. eCollection 2024. PLoS One. 2024. PMID: 38917111 Free PMC article.
References
-
- Wu M, Luo J; Online Journal of Nursing Informatics Contributors . Wearable technology applications in healthcare: a literature review. Healthcare Information and Management Systems Society. Accessed August 15, 2020. https://www.himss.org/resources/wearable-technology-applications-healthc...
-
- Device classification under section 513(f)(2)(de novo). FDA.gov. Accessed September 29, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=D...
-
- 510(k) premarket notification. FDA.gov. Accessed September 29, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=K142743
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
